SUO 2018: PSMA-Guided Salvage Lymph Node Dissection

Phoenix, Arizona (UroToday.com) Derya Tilki presented novel PSMA-guided salvage lymph node dissection (sLND) methodology. First, she started by reviewing the impact of biochemical recurrence (BCR) in prostate cancer outcomes.

SUO 2018: PROTUX Clinical Trial: Rituximab Neoadjuvant Therapy in High Risk Prostate Cancer Patients Scheduled to Undergo Radical Prostatectomy

Phoenix, Arizona (UroToday.com) To date, we have had little success with neoadjuvant therapies for high-risk localized prostate cancer (PCa) prior to definitive therapy with radical prostatectomy (RP). There are ongoing trials looking at the combination of chemotherapy, ADT and androgen-axis targeted therapies (ARATs), but these have yet to report.

SUO 2018: Gene Expression Classifier Utility in Men at High Risk of Recurrence Following Radical Prostatectomy (G-MINOR)

Phoenix, Arizona (UroToday.com) The Decipher assay is a molecular genomic biomarker based on tissue pathology that serves a genomic classifier (GC) for prostate cancer (PCa). It has previously been validated in the post-radical prostatectomy (RP) setting as a predictor of metastasis1 and therefore as a potential biomarker to determine the need for adjuvant radiotherapy in high-risk patients.2 However, all this work has been based on retrospective data and the authors of this study report on the first prospective randomized trial of the Decipher GC in this study population.

SUO 2018: Pathologic Progression is the Dominant Driver of Conversion to Radical Therapy Post Vascular

Phoenix, Arizona (UroToday.com) Partial gland ablation or focal therapy is an increasingly attractive option for men with high volume Gleason 6 disease or low-volume Gleason 7 disease that are on the borderline for active surveillance. While early results for focal therapy studies have been promising, with moderate oncologic benefit, feasible salvage in the setting of progression and preservation of sexual and urinary function, long-term oncologic data is lacking.

SUO 2018: Lithium Treatment Alters Histone Lysine Modification in Prostate Cancers

Phoenix, Arizona (UroToday.com) Lithium is an established treatment for psychiatric conditions, though with known significant side effects. However, in this phase 1 study, the authors assess lithium in men with localized prostate cancer (PCa). Current treatment paradigms for men with localized PCa are surgery or radiation, with no established systemic therapies.

SUO 2018: Treatment of the Primary Is Not Necessary, or Is It?

Phoenix, Arizona (UroToday.com) In this debate during the prostate cancer session, the two speakers look at the question of primary therapy for metastatic prostate cancer. Both ultimately agreed on the final message.

SUO 2018: Debate: Enucleo-Resection vs. Wedge Resection for Partial Nephrectomy in 4 cm tumors - PRO

Phoenix, Arizona (UroToday.com) In this debate Dr. Gupta presented his opinion on why renal tumors of less than 4 cm should be enucleated rather than undergo standard partial nephrectomy. Tumor enucleation is a common procedure which is defined as tumor excision along the natural plane between the peritumoral pseudo-capsule and the renal parenchyma, without removing a visible rim of normal parenchyma.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe